Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050309 | 0.83 | CHRM2 (0.54) | MLLT1PTPN1CHRM2CHRM1DRD1 | |
| SCHEMBL18974099 | 0.83 | CHRM2 (0.54) | MLLT1PTPN1CHRM2CHRM1DRD1 | |
| SCHEMBL2962439 | 0.83 | GRM5 (0.43) | MLLT1PTPN1CHRM2CHRM1DRD1 | |
| SCHEMBL3103383 | 0.83 | GRM5 (0.43) | MLLT1PTPN1CHRM2CHRM1DRD1 | |
| SCHEMBL2959581 | 0.83 | GRM5 (0.43) | MLLT1PTPN1CHRM2CHRM1DRD1 | |
| SCHEMBL8232564 | 0.81 | MAP4K4 (0.45) | MLLT1PTPN1CHRM2CHRM1DRD1 | |
| SCHEMBL16504181 | 0.81 | MAPK1 (0.50) | ALDH1A1SMN1; SMN2TP53RAB9ANPC1 | |
| SCHEMBL1844413 | 0.81 | MAPK1 (0.50) | ALDH1A1SMN1; SMN2TP53RAB9ANPC1 | |
| SCHEMBL1544213 | 0.81 | MAPK1 (0.50) | ALDH1A1SMN1; SMN2TP53RAB9ANPC1 | |
| SCHEMBL4041984 | 0.78 | SCD (0.43) | MLLT1TP53NOTUMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027128-A2 | FUSED HETEROCYLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | Astra Zeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130825-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259895-A1 | MGluR5 modulators VI | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1919901-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007130825-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259895-A1 | MGluR5 modulators VI | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259895-A1 | MGluR5 modulators VI | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259895-A1 | MGluR5 modulators VI | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| WO-2007021573-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259895-A1 | MGluR5 modulators VI | GRM5, GRIK5, GRM6 | MLLT1 3420/4885PTPN1 1977/4885CHRM2 423/4885 |
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | GRM5, GRM1, GRM2 | MLLT1 733/4885PTPN1 1307/4885CHRM2 268/4885 |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM2 | MLLT1 733/4885PTPN1 1307/4885CHRM2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.